SGSophia Gailhardou

Sophia Gailhardou

*This is an algorithmically generated author record based on publicly available information.

Sophia Gailhardou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

    by Sophia Gailhardou, Anna Skipetrova, Gustavo H. Dayan, John Jezorwski, Melanie Saville, Diane Van der Vliet, T. Anh Wartel

    A recombinant live attenuated tetravalent dengue vaccine (CYD-TDV) has been shown to be efficacious in preventing virologically-confirmed dengue disease, severe dengue disease and dengue hospitalization in children aged 2–16 years in Asia and Latin America. We analyzed pooled safety data from 18 phase I, II and III clinical trials in which the dengue vaccine was administered to participants aged 2–60 years, including long-term safety follow-up in three efficacy trials. The participants were analyzed according to their age at enrollment. The percentage of participants aged 2–60 years reporting ≥1 solicited injection-site or systemic reactions was slightly higher in the CYD-TDV group than in the placebo group. The most common solicited injection-site reactions were pain. Headache and malaise were the most common solicited systemic reactions. In both groups 0.3% of participants discontinued for safety reasons. The most common unsolicited adverse events were injection-site reactions, gastrointestinal disorders, and infections. Reactogenicity did not increase with successive doses of CYD-TDV. The frequency and nature of SAEs occurring within 28 days of any dose were similar in the CYD-TDV and placebo groups and were common medical conditions that could be expected as a function of age. Baseline dengue virus serostatus did not appear to influence the safety profile. No vaccine-related anaphylactic reactions, neurotropic events or viscerotropic events were reported. In year 3 after dose 1, an imbalance for dengue hospitalization, including for severe dengue, observed in participants aged <9 years in the CYD-TDV group compared with the placebo group was not observed for participants aged ≥9 years. In Year 4, this imbalance in participants aged <9 years was less marked, giving an overall lower risk of dengue hospitalization or severe dengue from dose 1 to Year 4 in the CYD-TDV group. These results have contributed to the definition of the target population for vaccination (≥9 years old) for which CYD-TDV has a satisfactory safety profile. Long-term safety will continue to be monitored in the ongoing follow-up of efficacy trials. Safety and effectiveness in real-life settings will be assessed through post-licensure studies. Dengue is a mosquito-borne viral infection in tropical and subtropical regions of the world that causes flu-like illness and, in severe cases, death. Every year, 390 million dengue infections occur worldwide, and over 3.9 billion people are now at risk from the disease. Although mosquito control and improved care have helped reduce dengue’s impact, a vaccine is needed. CYD-TDV, a live-attenuated vaccine, has been shown to be efficacious in preventing symptomatic virologically-confirmed dengue disease in children aged 2–16 years. To help establish its safety, we analyzed integrated data from available clinical trials, with emphasis on safety parameters suggested by the World Health Organization. The analysis included data for 77,234 doses in 26,356 participants aged 2–60 years who have received ≥1 dose. We found that the overall safety profile of the dengue vaccine is satisfactory. The imbalance observed for dengue hospitalization and severe dengue observed in year 3 after the first dose in children aged <9 years who had received CYD-TDV vaccine was less marked in year 4. This imbalance was not observed in participants aged ≥9 years in either year. These results have contributed to the definition of the target population for vaccination, i.e. ≥9 years old for which the CYD-TDV vaccine has a satisfactory safety profile.


  • Open Access

    Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children

    by Emmanuel Feroldi, Maria Rosario Capeding, Mark Boaz, Sophia Gailhardou, Claude Meric, Alain Bouckenooghe

    Japanese encephalitis chimeric virus vaccine (JE-CV) is a licensed vaccine indicated in a single dose administration for primary immunization. This controlled phase III comparative trial enrolled children aged 36–42 mo in the Philippines. 345 children who had received one dose of JE-CV in a study two years earlier, received a JE-CV booster dose. 105 JE-vaccine-naïve children in general good health were randomized to receive JE-CV (JE-vaccine naïve group; 46 children) or varicella vaccine (safety control group; 59 children). JE neutralizing antibody titers were assessed using PRNT50. Immunological memory was observed in children who had received the primary dose of JE-CV before. Seven days after the JE-CV booster dose administration, 96.2% and 66.8% of children were seroprotected and had seroconverted, respectively, and the geometric mean titer (GMT) was 231 1/dil. Twenty-eight days after the JE-CV booster dose seroprotection and seroconversion were achieved in 100% and 95.3% of children, respectively, and the GMT was 2,242 1/dil. In contrast, only 15.4% of JE-CV-vaccine naïve children who had not received any prior JE vaccine were seroprotected seven days after they received JE-CV. One year after receiving the JE-CV booster dose, 99.4% of children remained seroprotected. We conclude that JE-CV is effective and safe, both as a single dose and when administrated as a booster dose. A booster dose increases the peak GMT above the peak level reached after primary immunization and the antibody persistence is maintained at least one year after the JE-CV booster dose administration. Five year follow up is ongoing.